AVITA Medical (NASDAQ: RCEL) investors approve director pay, warrants and extra equity capacity
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
AVITA Medical, Inc. reported results of its 2026 annual stockholder meeting held by webcast. Of 30,776,689 common shares outstanding as of April 9, 2026, holders of 15,592,447 shares were represented, meeting quorum requirements.
Stockholders elected all seven director nominees and ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026. They approved increasing the non-executive directors’ aggregate annual cash fee pool from US$750,000 to US$900,000 and backed annual equity grants of restricted stock units and stock options to non-executive directors.
Initial equity grants to directors Michael Tarnoff and Joseph Woody were approved, along with an advisory vote in favor of named executive officer compensation and a preference for holding say-on-pay votes every one year. Stockholders also approved issuing warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP under an existing credit agreement and authorized the potential issuance of additional equity securities of up to 10% of issued capital under ASX Listing Rule 7.1A.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 5.07
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 30,776,689 shares
Shares represented at meeting: 15,592,447 shares
Non-exec director cash fee pool: US$900,000 per annum
+5 more
8 metrics
Shares outstanding
30,776,689 shares
Common stock outstanding and entitled to vote as of April 9, 2026
Shares represented at meeting
15,592,447 shares
Shares present or represented by proxy at the 2026 annual meeting
Non-exec director cash fee pool
US$900,000 per annum
New maximum aggregate annual cash fee pool, up from US$750,000
Annual equity grants per non-exec director
22,214 RSUs and 16,133 options
Approved annual grants to each non-executive director
Initial grant to Dr. Tarnoff
26,250 RSUs and 19,063 options
Initial equity award approved for director Michael Tarnoff
Initial grant to Joseph Woody
40,547 RSUs and 29,446 options
Initial equity award approved for director Joseph Woody
Perceptive warrants coverage
Up to 650,000 shares
Common stock underlying warrants with ten-year term to Perceptive Credit Holdings V, LP
Additional equity capacity
Up to extra 10% of issued capital
Potential equity securities issuance under ASX Listing Rule 7.1A
Key Terms
restricted stock units, Broker Non-Votes, ASX Listing Rule 7.1, ASX Listing Rule 7.1A, +2 more
6 terms
restricted stock units financial
"Stockholders approved the annual grants comprised of 22,214 restricted stock units and 16,133 stock options"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Broker Non-Votes financial
"Votes For | Votes Against | Abstentions | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
ASX Listing Rule 7.1 financial
"approved, for the purpose of ASX Listing Rule 7.1 (and all other purposes), the issuance of a warrant"
ASX Listing Rule 7.1A financial
"approved as a special resolution, for the purpose of ASX Listing Rule 7.1A"
Equity Securities financial
"the issue of Equity Securities (as defined in ASX Listing Rule 19.2) up to such additional 10% of the issued capital"
Equity securities are financial instruments that represent ownership shares in a company, like owning a slice of a pie that gives you a claim on its assets and future profits. They matter to investors because ownership can provide returns through price appreciation and occasional profit distributions, and may include voting power to influence company decisions, so their value reflects the firm’s performance and investor expectations.
advisory vote financial
"Advisory Vote to Approve Compensation of Named Executive Officers (Proposal 12)"
An advisory vote is a shareholder poll that expresses investors’ approval or concern about a company’s policy, executive pay, board decisions or other governance matters but does not legally force the company to act. Think of it like a customer survey: it signals investor sentiment and can pressure management to change course, so investors watch the result as a guide to future governance, risk and potential shifts in strategy.
FAQ
What did AVITA Medical (RCEL) stockholders approve at the 2026 annual meeting?
AVITA Medical stockholders approved all key proposals, including re-electing seven directors, ratifying Grant Thornton LLP as auditor, increasing the non-executive director fee pool, multiple equity award programs, new warrants, and additional equity issuance capacity under ASX Listing Rule 7.1A.
What change was approved to AVITA Medical’s non-executive director cash fee pool?
Stockholders approved raising the aggregate annual cash fee pool for non-executive directors from a maximum of US$750,000 per year to a maximum of US$900,000 per year, under ASX Listing Rule 10.17 and section 2.10 of the company’s amended and restated bylaws.
What equity awards did AVITA Medical (RCEL) stockholders approve for directors?
Stockholders approved annual grants of 22,214 restricted stock units and 16,133 stock options to each non-executive director, plus initial grants to Dr. Michael Tarnoff and Joseph Woody, all on terms described in the company’s definitive proxy statement filed on April 22, 2026.
What warrant issuance did AVITA Medical (RCEL) stockholders authorize?
Stockholders authorized issuance of a warrant or warrants covering up to 650,000 shares of common stock, with a ten-year term, to Perceptive Credit Holdings V, LP under a January 13, 2026 credit agreement, for purposes of ASX Listing Rule 7.1 and all other applicable purposes.
What additional equity capacity under ASX Listing Rule 7.1A did AVITA Medical gain?
Stockholders approved, as a special resolution, issuing equity securities of up to an additional 10% of the company’s issued capital in any 12-month period, calculated under ASX Listing Rule 7.1A.2, in addition to the standard 15% annual issuance limit.
How did AVITA Medical (RCEL) stockholders vote on executive compensation and say-on-pay frequency?
Stockholders supported the advisory vote approving named executive officer compensation and favored holding future advisory say-on-pay votes every one year, based on the vote tallies reported for Proposal 12 and Proposal 13 at the 2026 annual meeting.